Development of gene therapy using genome editing technologies

• HIRAMATSU Naoto

  Takeda Pharmaceutical Company Limited

• UCHIDA Eriko

  National Institute of Health Sciences

• INUKAI Naoto

  Takeda Pharmaceutical Company Limited

• IWAI Kenichi

  Takeda Pharmaceutical Company Limited

• WATANABE Takeshi

  Takeda Pharmaceutical Company Limited

• KAWASAKI Hideyoshi

  Astellas Pharma Inc.

• TAMURA Kotaro

  Astellas Pharma Inc.

• YOSHIMI Eiji

  Astellas Pharma Inc.

• TAKAHASHI Norihiko

  Otsuka Pharmaceutical Co., Ltd.

• IHARA Tatsuya

  Ono Pharmaceutical Company Limited

• FUJIMOTO Kazunori

  Daiichi Sankyo Company Limited

• YAMASHITA Akihito

  Sumitomo Dainippon Pharma Co., Ltd.

• ONO Takashi

  Ono Pharmaceutical Company Limited

• TAKAGI Kan

  Mitsubishi Tanabe Pharma Corporation

• ONO Ryuichi

  National Institute of Health Sciences

• NAITO Yuki

  Database Center for Life Science (DBCLS)

• INOUE Takao

  National Institute of Health Sciences

Bibliographic Information

Other Title

• ゲノム編集技術を用いた遺伝子治療の開発動向

Abstract

Today, gene therapy using gene editing tool (genome editing therapy) is becoming potential new modality treatment. But we need to consider it comes with unconventional safety issues. AMED research group and taskforce established in Japan Pharmaceutical Manufacturers Association have been cooperating in searching of genome editing therapy products and establishing a safety guideline for genome editing therapy. In this session, we will overview the landscape of genome editing therapy products development as the outcome of this co-working activity.

Journal

• Annual Meeting of the Japanese Society of Toxicology

  Annual Meeting of the Japanese Society of Toxicology 47.1 (0), S7-1-, 2020

  The Japanese Society of Toxicology

Details

• CRID: 1390004222615085568
• NII Article ID: 130007898567
• DOI: 10.14869/toxpt.47.1.0_s7-1
• Text Lang: ja
• Data Source:
  • JaLC
  • CiNii Articles
• Abstract License Flag: Disallowed